Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

December 12, 2007 09:00 ET

Holmes Biopharma, Inc.: Holmes Biopharma Returns to OTC Bulletin Board

SCOTTSDALE, ARIZONA--(Marketwire - Dec. 12, 2007) - Holmes Biopharma, Inc. (OTCBB:HLMB) is pleased to announce the company has been upgraded from reporting on the Pink Sheets to the OTC Bulletin Board. Trading on the OTCBB has begun under the stock symbol HLMB. In addition, the company has taken the initial steps to make a formal application for an AMEX listing.

"Holmes' return to the OTC Bulletin Board and resulting enhanced market exposure, creates a fantastic opportunity for investors to learn about our dynamic and growing organization," stated John F. Metcalfe, President and CEO. "This move will instill investor confidence to our existing shareholders as well as expose Holmes Biopharma to potential new investors," he added.

About Holmes Biopharma:

Holmes Biopharma, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services to the pharmaceutical industry and is actively involved in developing new drugs and drug delivery systems. Currently, clinics operate in Omaha, Nebraska USA, Toronto, Canada. and Kiev, Ukraine, Eastern Europe. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

Mr. John F. Metcalfe, President, CEO

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information